ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up

Alnylam Pharmaceuticals (ALNY) reported stronger-than-expected Q2 2025 results, with earnings of $0.32 per share reversing a prior loss and total revenues of $773.7 million significantly surpassing estimates. This outperformance was primarily driven by Amvuttra sales, which surged 114% year-over-year to $492 million due to expanded label indications and patient switches from Onpattro. Consequently, ALNY shares jumped 15.4%, and the company raised its 2025 product revenue guidance to $2.65-$2.8 billion, signaling continued strong growth prospects.

Analysis

Alnylam Pharmaceuticals (ALNY) reported a robust second quarter for 2025, decisively beating analyst expectations and signaling strong operational momentum. The company posted earnings of $0.32 per share, a significant reversal from the consensus estimate of a 3-cent loss, driven by total revenues of $773.7 million which surpassed the $673 million estimate. The core driver of this outperformance was a 64% year-over-year surge in net product revenues, headlined by its lead drug, Amvuttra. Amvuttra sales rocketed 114% to $492 million, fueled by strong patient uptake, successful conversion of patients from the older drug Onpattro (whose sales declined 32% to $52.5 million), and a recent label expansion into the ATTR-CM indication. This exceptional performance led management to substantially raise its full-year 2025 product revenue guidance to a range of $2.65-$2.8 billion, a notable increase from the prior $2.05-$2.25 billion. While total revenue growth was a more modest 17%, this was skewed by a non-recurring $185 million milestone payment from a collaborator in the year-ago quarter. Concurrently, operating expenses rose, with R&D up 11% and SG&A up 26%, reflecting strategic investments in late-stage trials and the commercial launch of Amvuttra's new indication. The market validated these results with a 15.4% increase in ALNY's share price, building on its 66.7% year-to-date gain.

Key Decisions for Investors

• Investors should recognize the significant upward revision of 2025 product revenue guidance as a strong validation of Amvuttra's powerful growth trajectory, which is further supported by its 114% year-over-year sales increase and recent label expansion.
• It is crucial to monitor the impact of rising operating expenses, with SG&A up 26% year-over-year, to ensure these investments in the Amvuttra launch and late-stage studies translate into sustained top-line growth and future profitability.
• Considering the stock's 15.4% surge on this news and 66.7% year-to-date performance, investors should weigh the powerful fundamental execution against the recent sharp price appreciation when considering new or additional positions.